Immutep Limited (IMMP): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMMP POWR Grades
- IMMP scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.96% of US stocks.
- IMMP's strongest trending metric is Value; it's been moving up over the last 177 days.
- IMMP ranks lowest in Momentum; there it ranks in the 5th percentile.
IMMP Stock Summary
- With a price/sales ratio of 38.84, IMMUTEP LTD has a higher such ratio than 95.78% of stocks in our set.
- With a year-over-year growth in debt of -83.28%, IMMUTEP LTD's debt growth rate surpasses just 2.22% of about US stocks.
- As for revenue growth, note that IMMP's revenue has grown -64.26% over the past 12 months; that beats the revenue growth of just 2.82% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to IMMUTEP LTD are OPT, ZYME, GOVX, IVA, and HIMX.
- IMMP's SEC filings can be seen here. And to visit IMMUTEP LTD's official web site, go to www.immutep.com.
IMMP Stock Price Chart Interactive Chart >
IMMP Price/Volume Stats
|Current price||$2.00||52-week high||$3.45|
|Prev. close||$1.93||52-week low||$1.47|
|Day high||$2.02||Avg. volume||92,533|
|50-day MA||$2.04||Dividend yield||N/A|
|200-day MA||$2.12||Market Cap||175.86M|
Immutep Limited (IMMP) Company Bio
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Most Popular Stories View All
IMMP Latest News Stream
|Loading, please wait...|
IMMP Latest Social Stream
View Full IMMP Social Stream
Latest IMMP News From Around the Web
Below are the latest news stories about IMMUTEP LTD that investors may wish to consider to help them evaluate IMMP as an investment opportunity.
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial. TACTI-003 is evaluating Immutep’s first-in-class soluble LAG-3 protein eftilagimod alpha (“efti”), in combination with MSD’s (Merck & Co., I
Immutep Limited ( ASX:IMM ) shareholders should be happy to see the share price up 12% in the last quarter. But that is...
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population expanded to include patients with triple-negative breast cancerLate-stage clinical development efforts remain focused on frontline non-small cell lung cancer (NSCLC) in combination with anti-PD-1 therapyImmutep’s cash runway extended to the end of the 1st half of calendar year 2024 SYDNEY, AUSTRALIA, Dec.
Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRALIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the successful scale-up of the manufacturing of its lead product candidate eftilagimod alpha (“efti” or “IMP321”), a first-in-clas
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune DiseasesMedia Release SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary prec
IMMP Price Returns